Analyst Faisal Khurshid of Leerink Partners reiterated a Buy rating on Pliant Therapeutics (PLRX – Research Report), retaining the price target of $33.00. Faisal Khurshid has given his Buy rating due ...
Analyst Edward Nash of Canaccord Genuity maintained a Buy rating on Pliant Therapeutics (PLRX – Research Report), retaining the price ...
Nov. 07, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a late-stage clinical biotechnology company and leader in the discovery and development of novel therapeutics for the ...
Pliant Therapeutics, Inc. (Nasdaq: PLRX), today announced that Keith Cummings, M.D., Chief Financial Officer, and Greg ...
Phase 2a trial results of Pliant Therapeutics' bexotegrast (PLN-74809) for idiopathic pulmonary fibrosis. Reduced lung collagen, improved FVC, and cough severity, signaling potential fibrosis ...
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a late-stage ...
About Pliant Therapeutics, Inc. Pliant Therapeutics is a late-stage biopharmaceutical company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback